Follow the Latest News from IMS

Call for Abstracts for the @Myeloma_Society Annual Meeting! Deadline is May 30. Click the link for more details: http://ow.ly/eJgn50HzKs1

Calling all young investigators! Applications for the Career Development Award are due on January 15. Learn more here: https://www.myelomasociety.org/grants/ims-career-development-award/

Apply today for the IMS and Paula and Rodger Riney Foundation Translational Research Award! Deadline is January 15. More details can be found here: http://ow.ly/9S4G50HrLwB

Calling all #ASH21 attendees - don't forget to stop by the @Myeloma_Society Booth in the exhibit hall! Learn more about our activities for 2022 and beyond.

This #GivingTuesday join @Myeloma_Society as we support the future of myeloma research and education worldwide. Donate today: http://ow.ly/clfV50GYslS

Calling all young investigators! Applications for the @Myeloma_Society Career Development Award are open until January 15! To apply, learn more or share, visit: http://ow.ly/SM4350GNHMH

.@Myeloma_Society is proud to announce applications are open for the second annual “IMS Translational Research Award” focused on funding research in the field of plasma cell dyscrasias. To apply, learn more, or share, visit: http://ow.ly/Nch250GNHFe

.@Myeloma_Society is proud to announce it is accepting applications for the second annual Translational Research and Career Development awards! Applications are open until January 15, 2022. Learn more and apply online: http://ow.ly/7sIM50GuuBY

After four days of exceptional science presented by #myeloma experts from around the globe, #IMW2021 has concluded. "Dankeschön" to all our in-person & virtual participants, our sponsors, and the wonderful host city of #Vienna! See you next August in Los Angeles, CA USA! #mmsm

Question asked in an #IMW2021 great debate today: "Which is the best immune approach to replace ASCT? CAR-T or bispecific antibodies?" After both debaters concluded their pitch, 67% of the audience decided the answer is "CAR-T." What's your answer? #myeloma #mmsm

3

Was the audience swayed re: their opinion on the question "can we give our patients treatment-free intervals?" The before (74% "yes") & after (79% "yes") of this #IMW2021 great debate in #myeloma remained virtually unchanged despite a well-informed counterargument. #mmsm

3

An #IMW2021 great debate in #myeloma entitled "Is stratification based on genomics ready for primetime?" pit husband against wife. Gareth Morgan (yes) and Faith Davies (no) held a good-natured exchange about this serious topic. The audience sided with Dr. Davies. #mmsm

3

#IMW2021 oral abstracts are a wrap. Some of the last shared conclusions: 3) Immune reactivity may help identify SMM patients who will benefit from early treatment with EloRD. #myeloma #mmsm @RomanosSP

#IMW2021 oral abstracts are a wrap. Some of the last shared conclusions: 2) Contemporary WB MRI as per MY-RADS criteria is significantly more sensitive to detect focal and diffuse disease than FDG PET/CT. #myeloma #mmsm @MyMKaiser

#IMW2021 oral abstracts are a wrap. Some of the last shared conclusions: 1) Although BM biopsy still remains the gold standard, cfDNA might be considered a suitable and less invasive marker; however more comparative studies needed. #myeloma #mmsm

Last day of #IMW2021 began w/@OncopeptidesUS-supported symposium. New therapies needed for RRMM—despite new combos & agents, survival of some patients remains poor. Lenrefractory, EMD, early relapse after ASCT, HR-CA, MRD persistence after optimized therapy among others. #myeloma

50 young #myeloma researchers received the IMS Exemplary Abstract Award at last night's IMS Awards Presentation. We're confident these young women and men will continue to deliver exceptional science and help us beat #MM. Congrats to all! Names here: https://bit.ly/2XjlOOJ #mmsm

Drug refractoriness is associated with inferior #myeloma outcomes was one conclusion shared in an #IMS2021 industry symposium supported by @Amgen. Presenters also identified PI/IMiD/CD38 mAb/BCMA-targeted therapy refractory as a new unmet medical need. #mmsm

IMS Exemplary Abstract Award recipients line up to receive their award at the #IMW2021 IMS Awards Presentation.🏆Let’s keep achieving great things to beat #myeloma! #mmsm

#IMW2021 Chair Heinz Ludwig welcomes hundreds to the IMW Awards Presentation and his home city of #Vienna as we celebrate achievements in #myeloma research. #mmsm

Load More...

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events